Loading…
Based on limited metadata, this FDA Warning Letter issued to Rxhomeo Private Limited on June 13, 2019, addresses compliance concerns related to drug products, though the specific nature of the violations cannot be determined as no subject line details are available. The letter falls under FDA's drug product regulatory authority, but without access to the full warning letter text, the particular manufacturing, quality, labeling, or other compliance issues cannot be identified. This warning indicates that the agency identified deficiencies significant enough to warrant formal notification to the company, requiring investigation of the complete letter for full details on required corrective actions.